Supplementary Figures 1 from Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study

• James W. Smithy
• , Hannah L. Kalvin
• , Fiona D. Ehrich
• , Ronak Shah
• , Matthew Adamow
• , Vladislav Raber
• , Collen A. Maher
• , Jenna Kleman
• , Deborah A.G. McIntyre
• , Alexander N. Shoushtari
• , Allison Betof Warner
• , Margaret K. Callahan
• , Parisa Momtaz
• , Omar Eton
• , Suresh Nair
• , Jedd D. Wolchok
• , Paul B. Chapman
• , Michael F. Berger
• , Katherine S. Panageas
• , Michael A. Postow